122
Views
6
CrossRef citations to date
0
Altmetric
Review

Economic assessment on the management of chronic lymphocytic leukaemia

, , &
Pages 1179-1189 | Published online: 15 Jun 2005

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Thitima Kongnakorn, James A Sterchele, Christopher G Salvador, Denis Getsios & Mkaya Mwamburi. (2014) Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis. ClinicoEconomics and Outcomes Research 6, pages 141-149.
Read now

Articles from other publishers (5)

Simon Frey, Carl R. Blankart & Tom Stargardt. (2016) Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature. PharmacoEconomics 34:5, pages 479-498.
Crossref
Nicolas Batty, Joseph Shatzel, Samuel Wiles, Mathew Kabalan, Rohit Sharma, Jonathan Pang, David Yi, Iris Alatovic, Sana Saif, Deepika Narasimha, Joseph LaPenna, Anthony Troitino, Kristopher Attwood, Michael Weinstein, Eric Murawski, Mathew Valerio, Yong Yin & Meir Wetzler. (2014) Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies. Journal of Cancer Policy 2:2, pages 40-44.
Crossref
Olena Mandrik, Isaac Corro Ramos, Olga Zalis’ka, Andriy Gaisenko & Johan L. Severens. (2013) Cost for Treatment of Chronic Lymphocytic Leukemia in Specialized Institutions of Ukraine. Value in Health Regional Issues 2:2, pages 205-209.
Crossref
Jennifer G. Gaultney, W.K. Redekop, Pieter Sonneveld & Carin A. Uyl-de Groot. (2011) Critical review of economic evaluations in multiple myeloma: An overview of the economic evidence and quality of the methodology. European Journal of Cancer 47:10, pages 1458-1467.
Crossref
. (2005) Current Awareness in Hematological Oncology. Hematological Oncology 23:3-4, pages 136-143.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.